22:15 uur 22-03-2021

VALBIOTIS verkrijgt ISO 9001-certificering voor zijn activiteiten in “Ontwerp, ontwikkeling en productiecontrole van oplossingen voor het voorkomen en bestrijden van metabole en cardiovasculaire aandoeningen”

LA ROCHELLE, Frankrijk – (BUSINESS WIRE) – Regelgevend nieuws:

VALBIOTIS (Parijs: ALVAL) (FR0013254851 – ALVAL/ komt in aanmerking voor de PEA/SME), een Frans onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van stofwisselingsziekten, kondigt aan dat het de ISO 9001-certificering heeft behaald voor zijn Quality Management System (QMS) ingezet op zijn drie locaties.

VALBIOTIS is door AFNOR volledig ISO 9001: 2015 gecertificeerd, met zes sterke punten, voor haar activiteiten in “Ontwerp, ontwikkeling en productiecontrole van oplossingen voor het voorkomen en bestrijden van metabole en cardiovasculaire ziekten”. Certificering wordt toegekend voor een periode van drie jaar, met jaarlijkse herevaluatie.

De ISO 9001: 2015 “Quality Management System” -standaard is internationaal erkend en definieert organisatorische vereisten die gericht zijn op het verbeteren van kwaliteit, prestaties en klanttevredenheid. Dit certificeringsproces garandeert en toont aan alle partners de controle over alle ontdekkingen, preklinisch onderzoek, klinisch onderzoek en productieactiviteiten, evenals het beheer van de productkwaliteit.

VALBIOTIS Obtains ISO 9001 Certification for Its Activities in “Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases”

LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has obtained ISO 9001 certification for its Quality Management System (QMS) deployed on its three sites.

VALBIOTIS has been awarded full ISO 9001:2015 certification by AFNOR, with six strong points, for its activities in “Design, development and production control of solutions for preventing and combating metabolic and cardiovascular diseases”. Certification is awarded for a period of three years, with annual re-evaluation.

The ISO 9001:2015 “Quality Management System” standard is internationally recognized and defines organizational requirements aimed at improving quality, performance and customer satisfaction. This certification process guarantees and demonstrates to all partners the control of all Discovery, Preclinical research, Clinical research and production activities, as well as product quality management.

Sébastien PELTIER, CEO and Chairman of the Executive Board, comments: “The organization of our quality management system since 2018 and the mobilization of all VALBIOTIS employees have been key in helping us achieve this objective. All the activities at our three sites (R&D Center in Riom, R&D Center in La Rochelle, Head Office in Périgny) have been awarded full ISO 9001 certification. This is a guarantee for all our current and future partners. It is particularly important given that our business model involves licensing our active substances to healthcare players and signing exclusive supply contracts. “

Cécile MERLE, Quality Assurance Director, adds: “In a context in which national and international regulatory and administrative requirements are increasingly rigorous and constantly evolving, and in which players are more and more demanding, it was essential to invest in this process. The strengths identified by AFNOR during the audit include the performance of our infrastructures, our ability to analyze and take into account the expectations of our stakeholders, as well as to effectively manage our risks and changes. The audit also highlighted our ability to control the quality of our R&D activities and the traceability and quality of our products, as well as to train and involve our staff in a continuous improvement process.”

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

For more information about VALBIOTIS, please visit: www.valbiotis.com.

Name: VALBIOTIS

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext© PEA-PME 150

DISCLAIMER

This press release contains forward-looking statements about VALBIOTIS’ objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company’s website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.

Contacts

VALBIOTIS / CORPORATE COMMUNICATION

Carole ROCHER / Marc DELAUNAY

+33 5 46 28 62 58

media@valbiotis.com

ACTIFIN / FINANCIAL COMMUNICATION

Stéphane RUIZ

+33 1 56 88 11 14

sruiz@actifin.fr

Check out our twitter: @NewsNovumpr